Le Lézard
Classified in: Covid-19 virus
Subject: ATY

OSCR LAWSUIT ALERT: Levi & Korsinsky Notifies Oscar Health, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline


NEW YORK, July 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Oscar Health, Inc. ("Oscar" or the "Company") (NYSE: OSCR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oscar investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/oscar-health-inc-loss-submission-form?prid=29558&wire=4 

OSCR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT'S NEXT? If you suffered a loss in Oscar during the relevant time frame, you have until July 11, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP


These press releases may also interest you

at 13:00
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 29, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II...

at 12:45
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 10:50
The "North America Dry Mix Mortar Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America)" report has been added to ResearchAndMarkets.com's offering....

at 09:00
Carbon Streaming Corporation (Cboe CA: NETZ) ("Carbon Streaming" or the "Company") provides an update on the Rimba Raya Project ("Rimba Raya" or the "Project"). The Company has learned of two third-party media reports that claim PT Rimba Raya...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
The latest data from the US Census Bureau reflects alarming statistics from those who have had COVID-19: 32.4% of adults aged 40-49 and 28.8% of those aged 30-39 report ever experiencing long COVID, grappling with debilitating symptoms such as...



News published on and distributed by: